219 related articles for article (PubMed ID: 37479763)
1. Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma.
Mangó K; Fekete F; Kiss ÁF; Erdős R; Fekete JT; Bűdi T; Bruckner E; Garami M; Micsik T; Monostory K
Sci Rep; 2023 Jul; 13(1):11770. PubMed ID: 37479763
[TBL] [Abstract][Full Text] [Related]
2. Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
Shu W; Guan S; Yang X; Liang L; Li J; Chen Z; Zhang Y; Chen L; Wang X; Huang M
Br J Clin Pharmacol; 2016 Feb; 81(2):327-40. PubMed ID: 26456622
[TBL] [Abstract][Full Text] [Related]
3. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA; Yong M; van Kan M; de Zoysa JR; Burns KE
Br J Clin Pharmacol; 2019 Sep; 85(9):1925-1934. PubMed ID: 31218720
[TBL] [Abstract][Full Text] [Related]
4. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
5. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.
Helsby NA; Hui CY; Goldthorpe MA; Coller JK; Soh MC; Gow PJ; De Zoysa JZ; Tingle MD
Br J Clin Pharmacol; 2010 Dec; 70(6):844-53. PubMed ID: 21175440
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 polymorphisms and the response of lupus nephritis to cyclophosphamide therapy.
Winoto J; Song H; Hines C; Nagaraja H; Rovin BH
Clin Nephrol; 2011 May; 75(5):451-7. PubMed ID: 21543025
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 Oxidoreductase Influences CYP2B6 Activity in Cyclophosphamide Bioactivation.
El-Serafi I; Afsharian P; Moshfegh A; Hassan M; Terelius Y
PLoS One; 2015; 10(11):e0141979. PubMed ID: 26544874
[TBL] [Abstract][Full Text] [Related]
8. Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.
Shu W; Chen L; Hu X; Zhang M; Chen W; Ma L; Liu X; Huang J; Pang T; Li J; Zhang Y
J Clin Pharmacol; 2017 Jul; 57(7):886-898. PubMed ID: 28181240
[TBL] [Abstract][Full Text] [Related]
9. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
10. Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition.
Wang PF; Sharma A; Montana M; Neiner A; Juriga L; Reddy KN; Tallchief D; Blood J; Kharasch ED
Br J Clin Pharmacol; 2022 Nov; 88(11):4881-4893. PubMed ID: 35538637
[TBL] [Abstract][Full Text] [Related]
11. Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a
Ming Z; Yongqiang Z; Zijin Z; Yan X; Di C; Xiaoxin T
Pharmacogenomics; 2019 Nov; 20(16):1119-1124. PubMed ID: 31686598
[TBL] [Abstract][Full Text] [Related]
12. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.
Yuce-Artun N; Baskak B; Ozel-Kizil ET; Ozdemir H; Uckun Z; Devrimci-Ozguven H; Suzen HS
Int J Clin Pharm; 2016 Apr; 38(2):388-94. PubMed ID: 26830411
[TBL] [Abstract][Full Text] [Related]
14. Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: a crucial role for the CYP2B6*6 allele.
Hwang IC; Park JY; Ahn HY; Kim KK; Suh HS; Ko KD; Kim KA
Clin Chim Acta; 2014 Jan; 428():77-81. PubMed ID: 24262967
[TBL] [Abstract][Full Text] [Related]
15. Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam.
Zubiaur P; Figueiredo-Tor L; Villapalos-García G; Soria-Chacartegui P; Navares-Gómez M; Novalbos J; Matas M; Calleja S; Mejía-Abril G; Román M; Ochoa D; Abad-Santos F
Biomed Pharmacother; 2022 Nov; 155():113747. PubMed ID: 36162369
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.
Jamieson D; Lee J; Cresti N; Jackson R; Griffin M; Sludden J; Verrill M; Boddy AV
Cancer Chemother Pharmacol; 2014 Oct; 74(4):667-74. PubMed ID: 25055937
[TBL] [Abstract][Full Text] [Related]
17. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
[TBL] [Abstract][Full Text] [Related]
18. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus.
Singh G; Saxena N; Aggarwal A; Misra R
J Rheumatol; 2007 Apr; 34(4):731-3. PubMed ID: 17407229
[TBL] [Abstract][Full Text] [Related]
20. Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide.
Audemard-Verger A; Martin Silva N; Verstuyft C; Costedoat-Chalumeau N; Hummel A; Le Guern V; Sacré K; Meyer O; Daugas E; Goujard C; Sultan A; Lobbedez T; Galicier L; Pourrat J; Le Hello C; Godin M; Morello R; Lambert M; Hachulla E; Vanhille P; Queffeulou G; Potier J; Dion JJ; Bataille P; Chauveau D; Moulis G; Farge-Bancel D; Duhaut P; Saint-Marcoux B; Deroux A; Manuzak J; Francès C; Aumaitre O; Bezanahary H; Becquemont L; Bienvenu B
PLoS One; 2016; 11(3):e0151696. PubMed ID: 27002825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
